Oncology Drugs to Watch 2021
16 July 2021 | Friday | Analysis
Key therapeutic candidates and forces shaping the oncology marketplace
Image Source : Public Domain
In this oncology edition of our Drugs to WatchTM series, Clarivate experts explore treatment breakthroughs highlighted at the ASCO Annual Meeting 2021, the biggest oncology event of the year, and provide analysis on how these will reshape the oncology landscape.
Key highlights from the report:
- Early-stage focus of most prominent treatments
- Gastroesophageal cancers as an emerging area of focus for biopharma
- Clash of the PD-1/PD-L1 titans
- Mainland China as an oncology powerhouse
Click here to Download an exclusive report
Most Read
- Lack of Regular Screening Fuels Rise in Late-Stage Breast Cancer in Hong Kong, New Report Reveals
- BIOCHINA 2025: Connecting Global Innovators with China's Leading Biotech Firms
- Leon Wyszkowski, President of Analytical Services, Discusses Thermo Fisher's Strategic Move: Expanding Bioanalytical Capabilities in Europe with New Sweden Lab
- The Role of Policy and Public Health Initiatives in Addressing Women's Cancer Care in Asia
- Redefining Patient Safety in the Age of Healthtech
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
Editor Picks
